Beactica Therapeutics’ small molecule platform enables the efficient development of innovative drug candidates

17 March 2021

Article in Dagens Industri Invest Talks, March 2021

With its powerful and versatile platform, Beactica Therapeutics identifies innovative small molecule drug candidates that have a targeted effect against carefully selected disease proteins. Strategic collaborations provide access to valuable knowledge and opportunities to work with a broader portfolio. We speak to the company's CEO, Dr Per Källblad.

Read the full original Swedish article here, and the translation in English here.


See all recent coverage

Stay Updated

Sign up for the Beactica newsletter to receive our latest news and updates

This website uses cookies to improve your user experience. By continuing to browse this site, you agree to our use of cookies. More information. Ok!